Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
Robert J.  Matusik

Robert J. Matusik, Ph.D.

William L. Bray Professor of Urologic Surgery
Professor of Cell & Developmental Biology, Cancer Biology
Director of Urologic Surgery Research
Researcher

Contact Information:

Vanderbilt University Medical Center
A-1302 Medical Center North
Nashville, TN 37232-2765
615-343-1902

Profile

Robert Matusik is professor of Urologic Surgery, Cancer Biology and Cell & Developmental Biology at Vanderbilt University School of Medicine and director of Urologic Research in the department of Urologic Surgery. He earned his PhD in biochemistry at the University of Rochester in New York in 1976 and completed a post-doctoral fellowship in cell biology at the Baylor College of Medicine in 1979.
Read more...

Robert Matusik is professor of Urologic Surgery, Cancer Biology and Cell & Developmental Biology at Vanderbilt University School of Medicine and director of Urologic Research in the department of Urologic Surgery. He earned his PhD in biochemistry at the University of Rochester in New York in 1976 and completed a post-doctoral fellowship in cell biology at the Baylor College of Medicine in 1979. Matusik joined the faculty of the University of Manitoba (Canada) Department of Physiology in 1979 and grew through the ranks to the position of full professor by the time he left in 1996 to join Vanderbilt?s faculty. He also served as a visit scientist for the British Columbia Cancer Agency, based in Vancouver, from 1992-1993.

Matusik holds numerous research grants from the National Institutes of Health and U.S. Department of Defense to support his research into the genetic, molecular and hormonal factors that contribute to the development and progression of prostate cancer. He also serves as a co-investigator in a Department of Defense grant to support development of a prostate cancer program at Meharry Medical College, a historically black institution in Nashville and a collaborator with Vanderbilt through the Meharry-Vanderbilt Alliance.

A former Damon Runyon-Walter Winchell fellow, Matusik has served on numerous study sections, site visit teams and review committees for the National Institutes of Health, the Department of Defense and the Department of Veterans Affairs. He also served on the editorial board of the journal Molecular Endocrinology.

Research Description

In North America, one in ten men is diagnosed with prostate cancer. Prostate cancer starts as an androgen dependent disease that progresses to an androgen independent cancer. The androgen independent tumors fail therapy. One of the major impediments to prostate cancer research is that no appropriate animal model system adequately displays the recognized stages of human prostatic disease. Further, no new therapeutic approaches have been developed after current therapy fails. Our laboratory has developed the probasin (PB) gene as a model system for androgen action, to establish new transgenic animal models for prostate cancer, and to test new therapeutic approaches for treatment.

The androgen receptor (AR) can function through similar cis-acting DNA elements similar to the palindromic glucocorticoid response element; however, recent data has shown that distinct AR elements (ARE) exist and function via cooperative interactions of multiple elements in the PB promoter. Further, since the PB promoter directs prostate specific expression in transgenic mice, it has become a model to dissect the key cis-acting DNA elements that control prostate-specific gene expression. Our laboratory has designed new PB promoters that target high levels of transgene expression to the prostate. These new promoters now serve to create new animal models for prostate cancer and to develop gene therapy vectors that will target a therapeutic gene(s) in the treatment of prostate cancer.

The PB promoter has been linked to oncogenes and growth factors to create new transgenic mouse models for prostate cancer. Transgenic mice carrying PB-oncogenes develop various stages of disease including prostatic precursor lesions that advance to an adenocarcinoma and then to high grade metastatic cancer. Gene expression profiles are being analyzed in these animal models to identify the key genes involved in tumor progression. By identifying the genes that are responsible for tumor progression, we can develop new targets for therapeutic intervention. .

Publications
  • Xie Y, Liu S, Lu W, Yang Q, Williams KD, Binhazim AA, Carver BS, Matusik RJ, Chen Z. Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Mol Oncol [print-electronic]. 2014 Oct; 8(7): 1355-64. PMID: 24910389, PMCID: PMC4198473, PII: S1574-7891(14)00111-2, DOI: 10.1016/j.molonc.2014.05.006, ISSN: 1878-0261.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24910389.
  • Grabowska MM, DeGraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD, Matusik RJ. Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev. 2014 Sep; 33(2-3): 377-97. PMID: 24452759, PMCID: PMC4108581, DOI: 10.1007/s10555-013-9487-8, ISSN: 1573-7233.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24452759.
  • DeGraff DJ, Grabowska MM, Case TC, Yu X, Herrick MK, Hayward WJ, Strand DW, Cates JM, Hayward SW, Gao N, Walter MA, Buttyan R, Yi Y, Kaestner KH, Matusik RJ. FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype. Lab. Invest [print-electronic]. 2014 Jul; 94(7): 726-39. PMID: 24840332, PMCID: PMC4451837, PII: labinvest201464, DOI: 10.1038/labinvest.2014.64, ISSN: 1530-0307.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24840332.
  • Grabowska MM, Elliott AD, DeGraff DJ, Anderson PD, Anumanthan G, Yamashita H, Sun Q, Friedman DB, Hachey DL, Yu X, Sheehan JH, Ahn JM, Raj GV, Piston DW, Gronostajski RM, Matusik RJ. NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression. Mol. Endocrinol [print-electronic]. 2014 Jun; 28(6): 949-64. PMID: 24801505, PMCID: PMC4042066, DOI: 10.1210/me.2013-1213, ISSN: 1944-9917.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24801505.
  • Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Matusik RJ. NF-¿B gene signature predicts prostate cancer progression. Cancer Res [print-electronic]. 2014 May 5/15/2014; 74(10): 2763-72. PMID: 24686169, PMCID: PMC4024337, PII: 0008-5472.CAN-13-2543, DOI: 10.1158/0008-5472.CAN-13-2543, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24686169.
  • Clayton DB, Stephany HA, Ching CB, Rahman SA, Tanaka ST, Thomas JC, Pope JC, Adams MC, Brock JW, Clark PE, Hayward SW, Matusik RJ, Milne GL. F2-isoprostanes as a biomarker of oxidative stress in the mouse bladder. J. Urol [print-electronic]. 2014 May; 191(5 Suppl): 1597-601. PMID: 24679873, PII: S0022-5347(13)05466-9, DOI: 10.1016/j.juro.2013.09.027, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24679873.
  • Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, Simmons CQ, Case TC, Yi J, Cates JM, Virostko J, He X, Jin X, Hayward SW, Matusik RJ, George AL, Yi Y. SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol [print-electronic]. 2013 Dec; 7(6): 1019-30. PMID: 23916135, PMCID: PMC3838491, PII: S1574-7891(13)00105-1, DOI: 10.1016/j.molonc.2013.07.008, ISSN: 1878-0261.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23916135.
  • Stephany HA, Strand DW, Ching CB, Tanaka ST, Milne GL, Cajaiba MM, Thomas JC, Pope JC, Adams MC, Brock JW, Hayward SW, Matusik RJ, Clayton DB. Chronic cyclic bladder over distention up-regulates hypoxia dependent pathways. J. Urol [print-electronic]. 2013 Oct; 190(4 Suppl): 1603-9. PMID: 23429070, PMCID: PMC4085185, PII: S0022-5347(13)00295-4, DOI: 10.1016/j.juro.2013.02.026, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23429070.
  • DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urol. Oncol [print-electronic]. 2013 Aug; 31(6): 802-11. PMID: 21924649, PII: S1078-1439(11)00237-7, DOI: 10.1016/j.urolonc.2011.07.017, ISSN: 1873-2496.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21924649.
  • Strand DW, DeGraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward WJ, Lin-Tsai O, Wang AY, Cates JM, Sloane BF, Matusik RJ, Hayward SW. Deficiency in metabolic regulators PPAR¿ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration. Am. J. Pathol [print-electronic]. 2013 Feb; 182(2): 449-59. PMID: 23219716, PMCID: PMC3562729, PII: S0002-9440(12)00801-2, DOI: 10.1016/j.ajpath.2012.10.007, ISSN: 1525-2191.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23219716.
  • Jin R, Sterling JA, Edwards JR, DeGraff DJ, Lee C, Park SI, Matusik RJ. Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PLoS ONE [print-electronic]. 2013; 8(4): e60983. PMID: 23577181, PMCID: PMC3618119, PII: PONE-D-12-24565, DOI: 10.1371/journal.pone.0060983, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23577181.
  • Drzewiecki BA, Anumanthan G, Penn HA, Tanaka ST, Thomas JC, Adams MC, Brock JW, Pope JC, Matusik RJ, Hayward S, Clayton DB. Modulation of the hypoxic response following partial bladder outlet obstruction. J. Urol [print-electronic]. 2012 Oct; 188(4 Suppl): 1549-54. PMID: 22910264, PII: S0022-5347(12)00392-8, DOI: 10.1016/j.juro.2012.02.037, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22910264.
  • DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS ONE [print-electronic]. 2012; 7(5): e36669. PMID: 22590586, PMCID: PMC3349679, PII: PONE-D-11-23587, DOI: 10.1371/journal.pone.0036669, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22590586.
  • Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ. Wnt/ß-catenin activation promotes prostate tumor progression in a mouse model. Oncogene [print-electronic]. 2011 Apr 4/21/2011; 30(16): 1868-79. PMID: 21151173, PMCID: PMC3081383, PII: onc2010560, DOI: 10.1038/onc.2010.560, ISSN: 1476-5594.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21151173.
  • Zhang J, Gao N, DeGraff DJ, Yu X, Sun Q, Case TC, Kasper S, Matusik RJ. Characterization of cis elements of the probasin promoter necessary for prostate-specific gene expression. Prostate. 2010 Jun 6/15/2010; 70(9): 934-51. PMID: 20209642, PMCID: PMC3712623, DOI: 10.1002/pros.21128, ISSN: 1097-0045.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20209642.
  • Nandana S, Ellwood-Yen K, Sawyers C, Wills M, Weidow B, Case T, Vasioukhin V, Matusik R. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model. Prostate. 2010 May 5/1/2010; 70(6): 591-600. PMID: 19938013, PMCID: PMC2925264, DOI: 10.1002/pros.21093, ISSN: 1097-0045.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19938013.
  • Jiang M, Fernandez S, Jerome WG, He Y, Yu X, Cai H, Boone B, Yi Y, Magnuson MA, Roy-Burman P, Matusik RJ, Shappell SB, Hayward SW. Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell Death Differ [print-electronic]. 2010 Mar; 17(3): 469-81. PMID: 19834493, PMCID: PMC2821953, PII: cdd2009148, DOI: 10.1038/cdd.2009.148, ISSN: 1476-5403.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19834493.
  • Sun Q, Yu X, Degraff DJ, Matusik RJ. Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression. Mol. Endocrinol [print-electronic]. 2009 Dec; 23(12): 2038-47. PMID: 19846536, PMCID: PMC2796152, PII: me.2009-0092, DOI: 10.1210/me.2009-0092, ISSN: 1944-9917.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19846536.
  • Anumanthan G, Tanaka ST, Adams CM, Thomas JC, Wills ML, Adams MC, Hayward SW, Matusik RJ, Bhowmick NA, Brock JW, Pope JC. Bladder stromal loss of transforming growth factor receptor II decreases fibrosis after bladder obstruction. J. Urol [print-electronic]. 2009 Oct; 182(4 Suppl): 1775-80. PMID: 19692014, PII: S0022-5347(09)01447-5, DOI: 10.1016/j.juro.2009.05.126, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19692014.
  • Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM, Taketo MM, Wills M, Matusik RJ. Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate. 2009 Feb 2/15/2009; 69(3): 249-62. PMID: 18991257, PMCID: PMC4437562, DOI: 10.1002/pros.20877, ISSN: 1097-0045.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18991257.
  • Li X, Wang Y, Sharif-Afshar AR, Uwamariya C, Yi A, Ishii K, Hayward SW, Matusik RJ, Bhowmick NA. Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling. Differentiation [print-electronic]. 2009 Jan; 77(1): 95-102. PMID: 19281768, PMCID: PMC2733217, PII: S0301-4681(08)00013-3, DOI: 10.1016/j.diff.2008.09.012, ISSN: 1432-0436.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19281768.
  • Anumanthan G, Makari JH, Honea L, Thomas JC, Wills ML, Bhowmick NA, Adams MC, Hayward SW, Matusik RJ, Brock JW, Pope JC. Directed differentiation of bone marrow derived mesenchymal stem cells into bladder urothelium. J. Urol [print-electronic]. 2008 Oct; 180(4 Suppl): 1778-83. PMID: 18721942, PII: S0022-5347(08)01140-3, DOI: 10.1016/j.juro.2008.04.076, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18721942.
  • Thomas JC, Oottamasathien S, Makari JH, Honea L, Sharif-Afshar AR, Wang Y, Adams C, Wills ML, Bhowmick NA, Adams MC, Brock JW, Hayward SW, Matusik RJ, Pope JC. Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells. J. Urol [print-electronic]. 2008 Oct; 180(4 Suppl): 1784-9. PMID: 18721943, PII: S0022-5347(08)00693-9, DOI: 10.1016/j.juro.2008.03.098, ISSN: 1527-3792.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18721943.
  • Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res. 2008 Aug 8/15/2008; 68(16): 6762-9. PMID: 18701501, PMCID: PMC2840631, PII: 68/16/6762, DOI: 10.1158/0008-5472.CAN-08-0107, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18701501.
  • Matusik RJ, Jin RJ, Sun Q, Wang Y, Yu X, Gupta A, Nandana S, Case TC, Paul M, Mirosevich J, Oottamasathien S, Thomas J. Prostate epithelial cell fate. Differentiation [print-electronic]. 2008 Jul; 76(6): 682-98. PMID: 18462434, PII: S0301-4681(09)60011-6, DOI: 10.1111/j.1432-0436.2008.00276.x, ISSN: 1432-0436.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18462434.
  • Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson EG, Shen MM, Matusik RJ, Hayward SW, Bhowmick NA. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res. 2008 Jun 6/15/2008; 68(12): 4709-18. PMID: 18559517, PMCID: PMC2811537, PII: 68/12/4709, DOI: 10.1158/0008-5472.CAN-07-6289, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18559517.
  • Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, Wills ML, Logan SK, Zhang P, Matusik RJ. Down-regulation of p57Kip2 induces prostate cancer in the mouse. Cancer Res. 2008 May 5/15/2008; 68(10): 3601-8. PMID: 18483241, PII: 68/10/3601, DOI: 10.1158/0008-5472.CAN-08-0073, ISSN: 1538-7445.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18483241.
  • Gupta A, Wang Y, Browne C, Kim S, Case T, Paul M, Wills ML, Matusik RJ. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate. 2008 Jan 1/1/2008; 68(1): 50-60. PMID: 18004726, DOI: 10.1002/pros.20650, ISSN: 0270-4137.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18004726.
  • Martinez-Ferrer M, Iturregui JM, Uwamariya C, Starkman J, Sharif-Afshar AR, Suzuki K, Visedsindh W, Matusik RJ, Dmochowski RR, Bhowmick NA. Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation. Am. J. Pathol [print-electronic]. 2008 Jan; 172(1): 59-67. PMID: 18079438, PMCID: PMC2189612, PII: S0002-9440(10)61462-9, DOI: 10.2353/ajpath.2008.070529, ISSN: 0002-9440.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18079438.
  • Suzuki K, Yu X, Chaurand P, Araki Y, Lareyre JJ, Caprioli RM, Orgebin-Crist MC, Matusik RJ. Epididymis-specific lipocalin promoters. Asian J. Androl. 2007 Jul; 9(4): 515-21. PMID: 17589789, DOI: 10.1111/j.1745-7262.2007.00300.x, ISSN: 1008-682X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17589789.
  • Oottamasathien S, Wang Y, Williams K, Franco OE, Wills ML, Thomas JC, Saba K, Sharif-Afshar AR, Makari JH, Bhowmick NA, DeMarco RT, Hipkens S, Magnuson M, Brock JW, Hayward SW, Pope JC, Matusik RJ. Directed differentiation of embryonic stem cells into bladder tissue. Dev. Biol [print-electronic]. 2007 Apr 4/15/2007; 304(2): 556-66. PMID: 17289017, PMCID: PMC1994155, PII: S0012-1606(07)00027-9, DOI: 10.1016/j.ydbio.2007.01.010, ISSN: 0012-1606.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17289017.
  • Wang Y, Kasper S, Yuan J, Jin RJ, Zhang J, Ishii K, Wills ML, Hayward SW, Matusik RJ. Androgen-dependent prostate epithelial cell selection by targeting ARR(2)PBneo to the LPB-Tag model of prostate cancer. Lab. Invest [print-electronic]. 2006 Oct; 86(10): 1074-88. PMID: 16894353, PII: 3700463, DOI: 10.1038/labinvest.3700463, ISSN: 0023-6837.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16894353.
  • Yu X, Suzuki K, Wang Y, Gupta A, Jin R, Orgebin-Crist MC, Matusik R. The role of forkhead box A2 to restrict androgen-regulated gene expression of lipocalin 5 in the mouse epididymis. Mol. Endocrinol [print-electronic]. 2006 Oct; 20(10): 2418-31. PMID: 16740652, PII: me.2006-0008, DOI: 10.1210/me.2006-0008, ISSN: 0888-8809.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16740652.
  • Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate. 2006 Jul 7/1/2006; 66(10): 1013-28. PMID: 16001449, DOI: 10.1002/pros.20299, ISSN: 0270-4137.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16001449.
  • Suzuki K, Yu X, Chaurand P, Araki Y, Lareyre JJ, Caprioli RM, Matusik RJ, Orgebin-Crist MC. Epididymis-specific promoter-driven gene targeting: a transcription factor which regulates epididymis-specific gene expression. Mol. Cell. Endocrinol [print-electronic]. 2006 May 5/16/2006; 250(1-2): 184-9. PMID: 16414179, PII: S0303-7207(05)00489-2, DOI: 10.1016/j.mce.2005.12.043, ISSN: 0303-7207.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16414179.
  • Lees JR, Charbonneau B, Hayball JD, Diener K, Brown M, Matusik R, Cohen MB, Ratliff TL. T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate. 2006 May 5/1/2006; 66(6): 578-90. PMID: 16388504, DOI: 10.1002/pros.20307, ISSN: 0270-4137.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16388504.
  • Uchida K, Masumori N, Takahashi A, Itoh N, Kato K, Matusik RJ, Tsukamoto T. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate. 2006 Apr 4/1/2006; 66(5): 536-45. PMID: 16372327, DOI: 10.1002/pros.20369, ISSN: 0270-4137.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16372327.
  • Shao TC, Li HL, Kasper S, Matusik R, Ittmann M, Cunningham GR. Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice. Prostate. 2006 Mar 3/1/2006; 66(4): 369-76. PMID: 16302273, DOI: 10.1002/pros.20354, ISSN: 0270-4137.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16302273.
  • Lees JR, Charbonneau B, Swanson AK, Jensen R, Zhang J, Matusik R, Ratliff TL. Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells. Immunology. 2006 Feb; 117(2): 248-61. PMID: 16423061, PMCID: PMC1782220, PII: IMM2293, DOI: 10.1111/j.1365-2567.2005.02293.x, ISSN: 0019-2805.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16423061.
  • Yu X, Gupta A, Wang Y, Suzuki K, Mirosevich J, Orgebin-Crist MC, Matusik RJ. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Ann. N. Y. Acad. Sci. 2005 Dec; 1061: 77-93. PMID: 16467259, PII: 1061/1/77, DOI: 10.1196/annals.1336.009, ISSN: 0077-8923.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16467259.
  • Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, González S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin. Cancer Res. 2005 Oct 10/1/2005; 11(19 Pt 1): 6823-34. PMID: 16203770, PMCID: PMC1432092, PII: 11/19/6823, DOI: 10.1158/1078-0432.CCR-05-0585, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16203770.
  • Ishii K, Shappell SB, Matusik RJ, Hayward SW. Use of tissue recombination to predict phenotypes of transgenic mouse models of prostate carcinoma. Lab. Invest. 2005 Sep; 85(9): 1086-103. PMID: 15980886, PII: 3700310, DOI: 10.1038/labinvest.3700310, ISSN: 0023-6837.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15980886.
  • Gao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer SR, Roberts RL, Jiang M, Yu X, Shappell SB, Caprioli RM, Stoffel M, Hayward SW, Matusik RJ. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development [print-electronic]. 2005 Aug; 132(15): 3431-43. PMID: 15987773, PII: dev.01917, DOI: 10.1242/dev.01917, ISSN: 0950-1991.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15987773.
  • Mirosevich J, Gao N, Matusik RJ. Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate. 2005 Mar 3/1/2005; 62(4): 339-52. PMID: 15389796, DOI: 10.1002/pros.20131, ISSN: 0270-4137.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15389796.
  • Yi Y, Mirosevich J, Shyr Y, Matusik R, George AL. Coupled analysis of gene expression and chromosomal location. Genomics. 2005 Mar; 85(3): 401-12. PMID: 15718107, PII: S0888-7543(04)00317-9, DOI: 10.1016/j.ygeno.2004.11.011, ISSN: 0888-7543.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15718107.
  • Suzuki K, Lareyre JJ, Sánchez D, Gutierrez G, Araki Y, Matusik RJ, Orgebin-Crist MC. Molecular evolution of epididymal lipocalin genes localized on mouse chromosome 2. Gene. 2004 Sep 9/15/2004; 339: 49-59. PMID: 15363845, PII: S0378111904003191, DOI: 10.1016/j.gene.2004.06.027, ISSN: 0378-1119.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15363845.
  • Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 2004 Aug 8/1/2004; 64(15): 5489-95. PMID: 15289359, PII: 64/15/5489, DOI: 10.1158/0008-5472.CAN-03-3117, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15289359.
  • Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. 2004 Aug; 6(2): 185-95. PMID: 15324701, PII: S1535610804002041, DOI: 10.1016/j.ccr.2004.07.008, ISSN: 1535-6108.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15324701.
  • Kirchhoff C, Araki Y, Huhtaniemi I, Matusik RJ, Osterhoff C, Poutanen M, Samalecos A, Sipilä P, Suzuki K, Orgebin-Crist MC. Immortalization by large T-antigen of the adult epididymal duct epithelium. Mol. Cell. Endocrinol. 2004 Mar 3/15/2004; 216(1-2): 83-94. PMID: 15109748, PII: S030372070300457X, DOI: 10.1016/j.mce.2003.10.073, ISSN: 0303-7207.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15109748.
  • Suzuki K, Drevet J, Hinton BT, Huhtaniemi I, Lareyre JJ, Matusik RJ, Pons E, Poutanen M, Sipilä P, Orgebin-Crist MC. Epididymis-specific promoter-driven gene targeting: a new approach to control epididymal function?. Mol. Cell. Endocrinol. 2004 Mar 3/15/2004; 216(1-2): 15-22. PMID: 15109740, PII: S0303720703004544, DOI: 10.1016/j.mce.2003.10.070, ISSN: 0303-7207.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15109740.
  • Masumori N, Tsuchiya K, Tu WH, Lee C, Kasper S, Tsukamoto T, Shappell SB, Matusik RJ. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J. Urol. 2004 Jan; 171(1): 439-42. PMID: 14665950, PII: S0022-5347(05)62775-9, DOI: 10.1097/01.ju.0000099826.63103.94, ISSN: 0022-5347.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/14665950.
  • Zhang J, Gao N, Kasper S, Reid K, Nelson C, Matusik RJ. An androgen-dependent upstream enhancer is essential for high levels of probasin gene expression. Endocrinology [print-electronic]. 2004 Jan; 145(1): 134-48. PMID: 14500578, PII: en.2003-0568, DOI: 10.1210/en.2003-0568, ISSN: 0013-7227.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/14500578.
  • Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 2003 Sep; 4(3): 223-38. PMID: 14522256, PII: S1535610803001971, ISSN: 1535-6108.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/14522256.
  • Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol [print-electronic]. 2003 Aug; 17(8): 1484-507. PMID: 12750453, PII: me.2003-0020, DOI: 10.1210/me.2003-0020, ISSN: 0888-8809.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12750453.
  • Wen Y, Giri D, Yan DH, Spohn B, Zinner RG, Xia W, Thompson TC, Matusik RJ, Hung MC. Prostate-specific antitumor activity by probasin promoter-directed p202 expression. Mol. Carcinog. 2003 Jul; 37(3): 130-7. PMID: 12884364, DOI: 10.1002/mc.10129, ISSN: 0899-1987.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12884364.
  • Shappell SB, Olson SJ, Hannah SE, Manning S, Roberts RL, Masumori N, Jisaka M, Boeglin WE, Vader V, Dave DS, Shook MF, Thomas TZ, Funk CD, Brash AR, Matusik RJ. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res. 2003 May 5/1/2003; 63(9): 2256-67. PMID: 12727848, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12727848.
  • Tu WH, Thomas TZ, Masumori N, Bhowmick NA, Gorska AE, Shyr Y, Kasper S, Case T, Roberts RL, Shappell SB, Moses HL, Matusik RJ. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia. 2003 May; 5(3): 267-77. PMID: 12869309, PMCID: PMC1502411, DOI: NO_DOI, ISSN: 1522-8002.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12869309.
  • Fouchécourt S, Lareyre JJ, Chaurand P, DaGue BB, Suzuki K, Ong DE, Olson GE, Matusik RJ, Caprioli RM, Orgebin-Crist MC. Identification, immunolocalization, regulation, and postnatal development of the lipocalin EP17 (epididymal protein of 17 kilodaltons) in the mouse and rat epididymis. Endocrinology. 2003 Mar; 144(3): 887-900. PMID: 12586765, DOI: 10.1210/en.2002-220932, ISSN: 0013-7227.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12586765.
  • Suzuki K, Araki Y, Zhu MY, Lareyre JJ, Matusik RJ, Orgebin-Crist MC. The 5'-flanking region of the murine epididymal protein of 17 kilodaltons gene targets transgene expression in the epididymis. Endocrinology. 2003 Mar; 144(3): 877-86. PMID: 12586764, DOI: 10.1210/en.2002-220757, ISSN: 0013-7227.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12586764.
  • Shappell SB., Masumori M, Thomas TZ, Case T, Paul M, Kasper S, Matusik RJ.. Transgenic mouse models of prostate carcinoma: Anatomic, Histopathologic, and molecular considerations. In: Prostate Cancer: Scientific and Clinical Aspects of Bridging the Gap, ed. by PD Abel and E-N Lalani. Imperial College Press (London). 2003; 245-319((Chapter 3)).
  • Logg CR, Logg A, Matusik RJ, Bochner BH, Kasahara N. Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J. Virol. 2002 Dec; 76(24): 12783-91. PMID: 12438603, PMCID: PMC136666, ISSN: 0022-538X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12438603.
  • Araki Y, Suzuki K, Matusik RJ, Obinata M, Orgebin-Crist MC. Immortalized epididymal cell lines from transgenic mice overexpressing temperature-sensitive simian virus 40 large T-antigen gene. J. Androl. 2002 Nov; 23(6): 854-69. PMID: 12399533, ISSN: 0196-3635.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12399533.
  • Song Z, Wu X, Powell WC, Cardiff RD, Cohen MB, Tin RT, Matusik RJ, Miller GJ, Roy-Burman P. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res. 2002 Sep 9/1/2002; 62(17): 5096-105. PMID: 12208767, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12208767.
  • Fouchécourt S, Chaurand P, DaGue BB, Lareyre JJ, Matusik RJ, Caprioli RM, Orgebin-Crist MC. Epididymal lipocalin-type prostaglandin D2 synthase: identification using mass spectrometry, messenger RNA localization, and immunodetection in mouse, rat, hamster, and monkey. Biol. Reprod. 2002 Feb; 66(2): 524-33. PMID: 11804971, ISSN: 0006-3363.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11804971.
  • Xie X, Zhao X, Liu Y, Zhang J, Matusik RJ, Slawin KM, Spencer DM. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res. 2001 Sep 9/15/2001; 61(18): 6795-804. PMID: 11559553, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11559553.
  • Andriani F, Nan B, Yu J, Li X, Weigel NL, McPhaul MJ, Kasper S, Kagawa S, Fang B, Matusik RJ, Denner L, Marcelli M. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J. Natl. Cancer Inst. 2001 Sep 9/5/2001; 93(17): 1314-24. PMID: 11535706, ISSN: 0027-8874.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11535706.
  • Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 2001 Mar 3/1/2001; 61(5): 2239-49. PMID: 11280793, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11280793.
  • Lareyre JJ, Winfrey VP, Kasper S, Ong DE, Matusik RJ, Olson GE, Orgebin-Crist MC. Gene duplication gives rise to a new 17-kilodalton lipocalin that shows epididymal region-specific expression and testicular factor(s) regulation. Endocrinology. 2001 Mar; 142(3): 1296-308. PMID: 11181548, DOI: 10.1210/endo.142.3.8045, ISSN: 0013-7227.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11181548.
  • Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 2001 Mar; 101(1-2): 61-9. PMID: 11231059, PII: S0925477300005517, ISSN: 0925-4773.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11231059.
  • Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, Dubois RN. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001 Jan 1/15/2001; 61(2): 497-503. PMID: 11212240, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11212240.
  • Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM, Tilley WD. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol. Endocrinol. 2001 Jan; 15(1): 46-56. PMID: 11145738, DOI: 10.1210/mend.15.1.0581, ISSN: 0888-8809.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11145738.
  • Lareyre JJ, Reid K, Nelson C, Kasper S, Rennie PS, Orgebin-Crist MC, Matusik RJ. Characterization of an androgen-specific response region within the 5' flanking region of the murine epididymal retinoic acid binding protein gene. Biol. Reprod. 2000 Dec; 63(6): 1881-92. PMID: 11090461, ISSN: 0006-3363.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11090461.
  • Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology. 2000 Dec; 141(12): 4698-710. PMID: 11108285, DOI: 10.1210/endo.141.12.7837, ISSN: 0013-7227.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11108285.
  • Kasper S, Matusik RJ. Rat probasin: structure and function of an outlier lipocalin. Biochim. Biophys. Acta. 2000 Oct 10/18/2000; 1482(1-2): 249-58. PMID: 11058766, PII: S0167-4838(00)00170-9, ISSN: 0006-3002.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11058766.
  • Kasper S, Rennie PS, Bruchovsky N, Lin L, Cheng H, Snoek R, Dahlman-Wright K, Gustafsson JA, Shiu RP, Sheppard PC, Matusik RJ. Selective activation of the probasin androgen-responsive region by steroid hormones. J. Mol. Endocrinol. 1999 Jun; 22(3): 313-25. PMID: 10343290, PII: JME00773, ISSN: 0952-5041.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10343290.
  • Lareyre JJ, Thomas TZ, Zheng WL, Kasper S, Ong DE, Orgebin-Crist MC, Matusik RJ. A 5-kilobase pair promoter fragment of the murine epididymal retinoic acid-binding protein gene drives the tissue-specific, cell-specific, and androgen-regulated expression of a foreign gene in the epididymis of transgenic mice. J. Biol. Chem. 1999 Mar 3/19/1999; 274(12): 8282-90. PMID: 10075734, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10075734.
  • Brash AR, Jisaka M, Boeglin WE, Chang MS, Keeney DS, Nanney LB, Kasper S, Matusik RJ, Olson SJ, Shappell SB. Investigation of a second 15S-lipoxygenase in humans and its expression in epithelial tissues. Adv. Exp. Med. Biol. 1999; 469: 83-9. PMID: 10667314, ISSN: 0065-2598.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10667314.
  • Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS. Differential transactivation by the androgen receptor in prostate cancer cells. Prostate. 1998 Sep 9/1/1998; 36(4): 256-63. PMID: 9719026, PII: 10.1002/(SICI)1097-0045(19980901)36:4<256::AID-PROS7>3.0.CO;2-D, ISSN: 0270-4137.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9719026.
  • Lareyre JJ, Mattéi MG, Kasper S, Ong DE, Matusik RJ, Orgebin-Crist MC. Genomic organization and chromosomal localization of the murine epididymal retinoic acid-binding protein (mE-RABP) gene. Mol. Reprod. Dev. 1998 Aug; 50(4): 387-95. PMID: 9669522, PII: 10.1002/(SICI)1098-2795(199808)50:4<387::AID-MRD2>3.0.CO;2-E, DOI: 10.1002/(SICI)1098-2795(199808)50:4<387::AID-MRD2>3.0.CO;2-E, ISSN: 1040-452X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9669522.
  • Green JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ, Scher HI. Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate. 1998 Jun 6/15/1998; 36(1): 59-63. PMID: 9650918, PII: 10.1002/(SICI)1097-0045(19980615)36:1<59::AID-PROS11>3.0.CO;2-H, ISSN: 0270-4137.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9650918.
  • Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab. Invest. 1998 Jun; 78(6): i-xv. PMID: 9645768, ISSN: 0023-6837.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9645768.
  • Lareyre JJ, Zheng WL, Zhao GQ, Kasper S, Newcomer ME, Matusik RJ, Ong DE, Orgebin-Crist MC. Molecular cloning and hormonal regulation of a murine epididymal retinoic acid-binding protein messenger ribonucleic acid. Endocrinology. 1998 Jun; 139(6): 2971-81. PMID: 9607808, DOI: 10.1210/endo.139.6.6074, ISSN: 0013-7227.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9607808.
  • Bai G, Kasper S, Matusik RJ, Rennie PS, Moshier JA, Krongrad A. Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells. J. Androl. 1998 Mar; 19(2): 127-35. PMID: 9570735, ISSN: 0196-3635.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9570735.
  • Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab. Invest. 1998 Mar; 78(3): 319-33. PMID: 9520945, ISSN: 0023-6837.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9520945.
  • Chan J, Song CS, Matusik RJ, Chatterjee B, Roy AK. Inhibition of androgen action by dehydroepiandrosterone sulfotransferase transfected in PC-3 prostate cancer cells. Chem. Biol. Interact. 1998 Feb 2/20/1998; 109(1-3): 267-78. PMID: 9566751, ISSN: 0009-2797.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9566751.
  • Lareyre JJ, Mattei M-G, Kasper S, Newcomer ME, Ong DE, Matusik RJ and Orgebin- Crist M-C. Structure and putative function of a murine epididymal retinoic acid-binding protein (mE-RABP). J. of Reprod. and Fert. Supplement. 1998; 53: 59-65.
  • Lareyre JJ, Mattei M-G, Kasper S, Ong DE, Matusik RJ and Orgebin-Crist M-C. Genomic organization and chromosomal localization of the murine epididymal retinoic acid binding protein (mE-RABP) gene. Mol. Reprod. and Dev. 1998; 50: 387-95.
  • Lareyre JJ, Mattéi MG, Kasper S, Newcomer ME, Ong DE, Matusik RJ, Orgebin-Crist MC. Structure and putative function of a murine epididymal retinoic acid-binding protein (mE-RABP). J. Reprod. Fertil. Suppl. 1998; 53: 59-65. PMID: 10645266, ISSN: 0449-3087.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10645266.
  • Lareyre JJ, Zheng WL, Zhao GQ, Kasper S, Newcomer ME, Matusik RJ, Ong DE and Orgebin-Crist MC. Molecular cloning and hormonal regulation of a murine epididymal retinoic acid-binding protein mRNA. Endocrinol. 1998; 139: 2971-81.
  • Yan Y, Sheppard PC, Kasper S, Lin L, Hoare S, Kapoor A, Dodd JG, Duckworth ML, Matusik RJ. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate. 1997 Jul 7/1/1997; 32(2): 129-39. PMID: 9215401, PII: 10.1002/(SICI)1097-0045(19970701)32:2<129::AID-PROS8>3.0.CO;2-H, ISSN: 0270-4137.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9215401.
  • Snoek R, Rennie PS, Kasper S, Matusik RJ, Bruchovsky N. Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides. J. Steroid Biochem. Mol. Biol. 1996 Nov; 59(3-4): 243-50. PMID: 9010316, PII: S0960-0760(96)00116-1, ISSN: 0960-0760.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9010316.
  • Barrios R, Lebovitz RM, Wiseman AL, Weisoly DL, Matusik RJ, DeMayo F and Lieberman MW. Ras T24 driven by a probasin promoter induces prostatic hyperplasia in transgenic mice. Transgenics. 1996; 2: 23-8.
  • Leonard MP, Sareen S, Hills K, Sheppard PC and Matusik RJ. Early characterization of a novel metastatic disease model of murine neuroblastoma. J. of Urol. 1996; 1565: 696-700.
  • Dubé JY, Chapdelaine P, Guérin S, Leclerc S, Rennie PS, Matusik RJ, Tremblay RR. Search for androgen response elements in the proximal promoter of the canine prostate arginine esterase gene. J. Androl. 1995 Jul; 16(4): 304-11. PMID: 8537247, ISSN: 0196-3635.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8537247.
  • Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U.S.A. 1995 Apr 4/11/1995; 92(8): 3439-43. PMID: 7724580, PMCID: PMC42182, ISSN: 0027-8424.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/7724580.
  • Levy I, Matusik RJ, Dodd J, Gallagher R and Meyer F. Joint workshop on laboratory aspects of proposed national prostate cancer screening trial: Part II. The establishment of a biorepository (Laboratory Centre for Disease Control, Health Canada). Chronic Diseases of Canada. 1995; 16: 129-30.
  • Dedhar S, Rennie PS, Shago M, Hagesteijn CY, Yang H, Filmus J, Hawley RG, Bruchovsky N, Cheng H, Matusik RJ. Inhibition of nuclear hormone receptor activity by calreticulin. Nature. 1994 Feb 2/3/1994; 367(6462): 480-3. PMID: 8107809, DOI: 10.1038/367480a0, ISSN: 0028-0836.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8107809.
  • Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Dodd JG, Duckworth ML, Rosen RJ and Matusik R. The rat probasin gene promoter directs hormonally-and developmentally-regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Molecular Endocrinology. 1994; 8: 230-9.
  • Kasper S, Rennie PS, Bruchovsky N, Sheppard PC, Cheng H, Lin L, Shin RPC, Snoek R and Matusik RJ. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J. of Biol. Chem. 1994; 269: 31763-9.
  • Kazemi-Esfajani P, Beitel L, Trifiro M, Kaufman M, Rennie PS, Sheppard P, Matusik RJ, and Pinsky L. Substitution of valine 865 by methionine or leucine causes complete or partial androgen insensitivity, respectively with distinct androgen receptor phenotype. Molecular Endocrinology. 1993; 7: 37-46.
  • Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Block ME, MacDonald BS Nickel BE, Chang C, Liao, S, Cattini PA and Matusik RJ. Characterization of two cis-acting elements involved in the androgen regulation of the probasin gene. Molecular Endocrinology. 1993; 7: 23-36.
  • Berczi I, Nagy E, de Toledo SM, Matusik RJ, Friesen HG. Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue. J. Immunol. 1991 Apr 4/1/1991; 146(7): 2201-6. PMID: 2005393, ISSN: 0022-1767.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2005393.
  • Harris SE, Harris MA, Johnson CM, Bean MF, Dodd JG, Matusik RJ, Carr SA, Crabb JW. Structural characterization of the rat seminal vesicle secretion II protein and gene. J. Biol. Chem. 1990 Jun 6/15/1990; 265(17): 9896-903. PMID: 2351680, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2351680.
  • Spence AM, Sheppard PC, Davie JR, Matuo Y, Nishi N, McKeehan WL, Dodd JG, Matusik RJ. Regulation of a bifunctional mRNA results in synthesis of secreted and nuclear probasin. Proc. Natl. Acad. Sci. U.S.A. 1989 Oct; 86(20): 7843-7. PMID: 2682630, PMCID: PMC298167, ISSN: 0027-8424.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2682630.
  • Matuo Y, Adams PS, Nishi N, Yasumitsu H, Crabb JW, Matusik RJ, McKeehan WL. The androgen-dependent rat prostate protein, probasin, is a heparin-binding protein that co-purifies with heparin-binding growth factor-1. In Vitro Cell. Dev. Biol. 1989 Jun; 25(6): 581-4. PMID: 2472375, ISSN: 0883-8364.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2472375.
  • Sweetland R, Sheppard PC, Dodd JG, Matusik RJ. Post-castration rebound of an androgen regulated prostatic gene. Mol. Cell. Biochem. 1988 Nov; 84(1): 3-15. PMID: 2466196, ISSN: 0300-8177.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2466196.
  • Matusik RJ, Fleming WH, Hamel A, Westenbrink TG, Hrabarchuk B, MacDonald R, Ramsey E, Gartner JG, Pettigrew NM, Johnston B. Expression of the c-myc proto-oncogene in prostatic tissue. Prog. Clin. Biol. Res. 1987; 239: 91-112. PMID: 2443918, ISSN: 0361-7742.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2443918.
  • Dodd JG, Kreis C, Sheppard PC, Hamel A, Matusik RJ. Effect of androgens on mRNA for a secretory protein of rat dorsolateral prostate and seminal vesicles. Mol. Cell. Endocrinol. 1986 Oct; 47(3): 191-200. PMID: 3758473, ISSN: 0303-7207.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/3758473.
  • Matusik RJ, Kreis C, McNicol P, Sweetland R, Mullin C, Fleming WH, Dodd JG. Regulation of prostatic genes: role of androgens and zinc in gene expression. Biochem. Cell Biol. 1986 Jun; 64(6): 601-7. PMID: 3741677, ISSN: 0829-8211.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/3741677.
  • Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, Dodd JG, Matusik RJ. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res. 1986 Mar; 46(3): 1535-8. PMID: 2417706, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2417706.
  • Fleming WH, Murphy PR, Murphy LJ, Hatton TW, Matusik RJ, Friesen HG. Human growth hormone induces and maintains c-myc gene expression in Nb2 lymphoma cells. Endocrinology. 1985 Dec; 117(6): 2547-9. PMID: 4065045, DOI: 10.1210/endo-117-6-2547, ISSN: 0013-7227.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/4065045.
  • Dodd JG, Sheppard PC, Matusik RJ. Characterization and cloning of rat dorsal prostate mRNAs. Androgen regulation of two closely related abundant mRNAs. J. Biol. Chem. 1983 Sep 9/10/1983; 258(17): 10731-7. PMID: 6193116, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/6193116.
  • Fleming WH, Pettigrew NM, Matusik RJ, Friesen HG. Thymic origin of the prolactin-dependent Nb2 lymphoma cell line. Cancer Res. 1982 Aug; 42(8): 3138-41. PMID: 7046917, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/7046917.
  • Matusik RJ, Rosen JM. Prolactin regulation of casein gene expression: possible mediators. Endocrinology. 1980 Jan; 106(1): 252-9. PMID: 6243098, DOI: 10.1210/endo-106-1-252, ISSN: 0013-7227.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/6243098.
  • Rosen JM, Matusik RJ, Richards DA, Gupta P, Rodgers JR. Multihormonal regulation of casein gene expression at the transcriptional and posttransciptional levels in the mammary gland. Recent Prog. Horm. Res. 1980; 36: 157-93. PMID: 6997941, ISSN: 0079-9963.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/6997941.
  • Guyette WA, Matusik RJ, Rosen JM. Prolactin-mediated transcriptional and post-transcriptional control of casein gene expression. Cell. 1979 Aug; 17(4): 1013-23. PMID: 487427, PII: 0092-8674(79)90340-4, ISSN: 0092-8674.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/487427.
  • Matusik RJ, Rosen JM. Prolactin induction of casein mRNA in organ culture. A model system for studying peptide hormone regulation of gene expression. J. Biol. Chem. 1978 Apr 4/10/1978; 253(7): 2343-7. PMID: 632273, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/632273.
  • Matusik RJ, Hilf R. Relationship of adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate to growth of dimethylbenz(a)anthracene-induced mammary tumors in rats. J. Natl. Cancer Inst. 1976 Mar; 56(3): 659-61. PMID: 176403, ISSN: 0027-8874.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/176403.